Medicine and Dentistry
Therapeutic Procedure
100%
Non-Hodgkin Lymphoma
100%
B-Cell Chronic Lymphocytic Leukemia
100%
B Cell
100%
Rituximab
100%
Bendamustine
100%
Multiple Myeloma
17%
Benzimidazole
17%
Purine
13%
Combination Therapy
8%
Toxicity
8%
Patient
8%
Drug
8%
Chemotherapeutic Agent
8%
Clinical Study
8%
Adverse Event
8%
Progression Free Survival
8%
Interim Analysis
8%
Parent
4%
In Vitro
4%
Alkylating Antineoplastic Agent
4%
Breast Cancer
4%
Pharmacodynamics
4%
Hematologic Malignancy
4%
Cancer
4%
Inpatient
4%
Infection
4%
Arm
4%
Assay
4%
Amino Acid
4%
Chlormethine
4%
Hematology
4%
Spontaneous Remission
4%
Monotherapy
4%
Fatigue
4%
Bioavailability
4%
Fever
4%
Active Metabolite
4%
Isoprenaline
4%
Progressive Disease
4%
First Pass Effect
4%
Xerostomia
4%
Clinical Oncology
4%
Hodgkin's Lymphoma
4%
Cross Resistance
4%
Nausea
4%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Chronic Lymphatic Leukemia
100%
Rituximab
100%
Bendamustine
100%
Multiple Myeloma
17%
Benzimidazole
17%
Chlorambucil
17%
Chlormethine Derivative
13%
Toxicity
8%
Drug
8%
Progression Free Survival
8%
Adverse Event
8%
Purine
8%
Diseases
4%
Alkylating Agent
4%
Breast Cancer
4%
Nitrogen Mustard
4%
Infection
4%
Monotherapy
4%
Pharmacodynamics
4%
Glycine
4%
Remission
4%
Fatigue
4%
Fever
4%
Bioavailability
4%
Nausea
4%
Isoprenaline
4%
Active Metabolite
4%
Hematologic Malignancy
4%
CYP1A2
4%
Cross-Resistance
4%
Hodgkin Disease
4%
Xerostomia
4%
Purine Derivative
4%